## 12th JOINT MEETING

#### OF

#### **BRITISH ENDOCRINE SOCIETIES**

29 March - 1 April 1993 Liverpool

These abstracts are published in good faith exactly as received from the submitting authors. The opinions and views within are those of the submitting authors and have not been verified by the Societies, who accept no scientific responsibility for the statements made or for their content. It is not possible to guarantee that the abstracts printed in this Supplement will be presented at the Meeting.

12

Μ

© 1993 Journal of Endocrinology Ltd

Find authenticated court documents without watermarks at docketalarm.com.

## **BRITISH ENDOCRINE SOCIETIES**

#### **Benefactors**

Clinical Endocrinology Trust Farmitalia Carlo Erba Ferring Pharmaceuticals Kabi Pharmacia Novo Nordisk Sandoz Pharmaceuticals Serono Laboratories ZENECA Pharma

## CONTENTS

## PLENARY LECTURERS' BIOGRAPHICAL NOTES

FLENKR LECTORESS1Society for Endocrinology Dale Medal LectureS1Society for Endocrinology Transatlantic Medal LectureS3Thyroid Club Pitt-Rivers LectureS4Clinical Endocrinology Trust LectureS5Royal Society of Medicine LectureS5SVMPOSIASteroids and the brainParacrinology of early pregnancyS11-S14Angiogenesis as an endocrine responseS15-S18Aetiology of endocrine tumoursS19-S22Renin-angiotensin-aldoterone axisS23-S26Endocrine autoimmunityS27-S31CLINICAL MANAGEMENT WORKSHOPSS32-S33Endocrine management of breast cancerS32-S33Non-isotopic in-silu hybridizationS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrino pathologyOC29-OC33Steroid actionP27-P40DiabetesP41-P50Dorderine pathologyOC29-OC33SteroidogenesisCC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50DiabetesP41-P50Polaceine pathologyP51-P57GrowthP68-P89MethodologyP90-P88	PLENARY LECTURES	
Society for Endocrinology Dale Medal Lecture \$2 Society for Endocrinology Dale Medal Lecture \$3 Thyroid Club Pitt-Rivers Lecture \$3 Royal Society of Medicine Lecture \$35 Royal Society of Medicine Lecture \$35 Royal Society of Medicine Lecture \$35 SYMPOSIA \$35 Paracrinology of early pregnancy \$11-514 Angiogenesis as an endocrine response \$15-518 Aetiology of endocrine tumours \$19-522 Renin-angiotensin-aldosterone axis \$23-526 Endocrine autoimmunity \$27-531 CLINICAL MANAGEMENT WORKSHOPS Endocrine management of breast cancer \$23-833 Thyroid eye disease \$34-835 Secondary osteoporosis \$36-838 METHODS UPDATES \$36-838 METHODS UPDATES \$36-838 METHODS UPDATES \$39-840 Gonadotrophin bioassay versus immunoassay \$41 RESEARCH COLLOQUIA \$42, RC1-RC4 Intracellular signalling \$43, RC5-RC8 ORAL COMMUNICATIONS \$00 Growth \$00C1-00C5 Reproduction \$00C1-00C3 Reproduction \$00C1-00C3 Steroidogenesis \$00C34-00C33 Steroidogenesis \$00C34-00C33 Steroidogenesis \$00C34-00C33 Steroidogenesis \$00C34-00C33 Steroidogenesis \$00C34-00C33 Steroidogenesis \$00C34-00C33 Steroidogenesis \$00C34-00C34 OC1		S1
Society for Endocrinology Transatlantic Medal Lecture S3 Thyroid Club Pitt-Rivers Lecture S4 Clinical Endocrinology Trust Lecture S5 Royal Society of Medicine Lecture S5 SYMPOSIA Steroids and the brain S7-S10 Paracrinology of early pregnancy S11-S14 Angiogenesis as an endocrine response S15-S18 Aetiology of endocrine tumours S19-S22 Renin-angiotensin-aldosterone axis S23-S26 Endocrine autoimmunity S27-S31 CLINICAL MANAGEMENT WORKSHOPS Endocrine management of breast cancer S32-S33 Thyroid eye disease S34-S35 Secondary osteoporosis S36-S38 METHODS UPDATES Non-isotopic in-situ hybridization S39-S40 Gonadotrophin bioassay versus immunoassay S41 RESEARCH COLLOQUIA Steroid action S42, RC1-RC4 Intracellular signalling OC1-OC5 Reproduction OC12-OC17 Thyroid OC18-OC28 Neuroendocrinology OC29-OC33 Steroidogenesis OC34-OC38 Rester PRESENTATIONS Adrenal P1-P26 Bone and calcium P27-P40 Diabetes P46-P30-P66-P86-P86-P86-P86-P86-P86-P86-P86-P86		
Sockey for Linear LectureS4Chinical Endocrinology Trust LectureS5Royal Society of Medicine LectureS6SYMPOSIAS1-S10Paracrinology of early pregnancyS11-S11Angiogenesis as an endocrine responseS15-S18Actiology of endocrine tumoursS19-S22Renin-angiotensin-aldosterone axisS23-S26Endocrine management of breast cancerS32-S33CLINCAL MANAGEMENT WORKSHOPSS16-S38Endocrine management of breast cancerS32-S33Secondary osteoporosisS36-S38METHODS UPDATESS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC73NeuroendocrinologyOC29-OC33Steroid actionP1-P26Bone and calciumP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67Endocrine pathologyP51-P67Endocrine pathologyP68-P89From Muthice PathologyP68-P89 <tr< td=""><td></td><td></td></tr<>		
Infinite Line InfinitesS5Royal Society of Medicine Lecture\$6SYMPOSIA\$11-514Steroids and the brain\$7-\$10Paracrinology of early pregnancy\$11-\$14Angiogenesis as an endocrine response\$15-\$18Actiology of endocrine tumours\$19-\$222Renin-angiotensin-aldosterone axis\$23-\$26Endocrine autoimmunity\$27-\$31CLINICAL MANAGEMENT WORKSHOPS\$32-\$33Endocrine autoimmunity\$34-\$35Secondary osteoporosis\$34-\$35Secondary osteoporosis\$36-\$38METHODS UPDATES\$39-\$40Gonadotrophin bioassay versus immunoassay\$41RESEARCH COLLOQUIA\$42, RC1-RC4Intracellular signalling\$43, RC5-RC8ORAL COMMUNICATIONS\$00-10-05Growth\$00-20-0033POSTER PRESENTATIONS\$00-20-0033POSTER PRESENTATIONS\$00-20-00-003POSTER PRESENTATIONS\$11-\$27.\$40Diabetes\$11-\$27.\$40Diabetes\$11-\$27.\$40Diabetes\$11-\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$27.\$40Poster Reproduction\$47.\$40Poster Reproduction\$47.\$40Poster Reproduction <t< td=""><td>•</td><td></td></t<>	•	
Chinkin Linkerinology Think DeckineS6Royal Society of Medicine LectureS6SYMPOSIASteroids and the brainSteroids and the brainS7-S10Paracrinology of early pregnancyS11-S14Angiogenesis as an endocrine responseS19-S22Renin-angiotensin-aldosterone axisS23-S26Endocrine autoimmunityS27-S31CLINICAL MANAGEMENT WORKSHOPSS19-S22Endocrine management of breast cancerS32-S33Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATESS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC2-OC11Endocrine pathologyOC1-OC5NeuroendocrinologyOC2-OC23Steroid actionOC1-OC5RepoductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5ReproductionOC1-OC5Reproduction <t< td=""><td></td><td></td></t<>		
SYMPOSIA S7-S10   Paracrinology of early pregnancy S11-S14   Angiogenesis as an endocrine response S15-S18   Aetiology of endocrine tumours S19-S22   Renin-angiotensin-aldosterone axis S23-S26   Endocrine autoimmunity S27-S31   CLINICAL MANAGEMENT WORKSHOPS S32-S33   Endocrine management of breast cancer S32-S33   Thyroid eye disease S34-S35   Secondary osteoporosis S36-S38   METHODS UPDATES S39-S40   Non-isotopic in-situ hybridization S39-S40   Gonadotrophin bioassay versus immunoassay S41   RESEARCH COLLOQUIA S42, RC1-RC4   Intracellular signalling S43, RC5-RC8   ORAL COMMUNICATIONS OC1-OC5   Growth OC18-OC23   Neuroendocrinology OC29-OC33   Steroid action P1-P26   Bone and calcium P27-P40   Diabetes P1-P26   Bone and calcium P27-P40   Diabetes P1-P26   Bone and calcium P27-P40   Diabetes P41-P50   Endocrine pathology		
Steroids and the brainS7-S10Paracrinology of early pregnancyS11-S14Angiogenesis as an endocrine responseS15-S18Actiology of endocrine tumoursS19-S22Renin-angiotensin-aldosterone axisS23-S26Endocrine autoimmunityS27-S31CLINICAL MANAGEMENT WORKSHOPSS10-S23Endocrine management of breast cancerS32-S33Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATESS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC18-OC28NeuroendocrinologyOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26AdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89P68-P89P51-P67GrowthP68-P80Pati-P50P41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50Pate PathologyP51-P67GrowthP68-P80P68-P80P51-P67GrowthP70-P40SteroidogenesisP41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50	Royal Society of Medicine Lecture	06
Steroids and the brainS7-S10Paracrinology of early pregnancyS11-S14Angiogenesis as an endocrine responseS15-S18Actiology of endocrine tumoursS19-S22Renin-angiotensin-aldosterone axisS23-S26Endocrine autoimmunityS27-S31CLINICAL MANAGEMENT WORKSHOPSS10-S23Endocrine management of breast cancerS32-S33Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATESS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC18-OC28NeuroendocrinologyOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26AdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89P68-P89P51-P67GrowthP68-P80Pati-P50P41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50Pate PathologyP51-P67GrowthP68-P80P68-P80P51-P67GrowthP70-P40SteroidogenesisP41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50SteroidogenesisP41-P50	CVMDORIA	
Solutions and other\$11-\$14Angiogenesis as an endocrine response\$15-\$18Aetiology of endocrine tumours\$19-\$22Renin-angiotensin-aldosterone axis\$23-\$26Endocrine autoimmunity\$27-\$31CLINICAL MANAGEMENT WORKSHOPS\$32-\$33Endocrine management of breast cancer\$32-\$33Thyroid eye disease\$34-\$35Secondary osteoporosis\$36-\$38METHODS UPDATES\$39-\$40Gonadotrophin bioassay versus immunoassay\$41RESEARCH COLLOQUIA\$42, RC1-RC4Steroid action\$42, RC1-RC4Intracellular signalling\$43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26AdrenalP1-P26Bone and calcium\$27.P40Diabetes\$91.P67Growth\$91.P67Growth\$91.P67Growth\$91.P67Growth\$91.P67Gone and calcium\$91.P67Growth\$91.P67Growth\$94.P50Patersis\$91.P67Growth\$91.P67Growth\$92.P49Steroidogenesis\$91.P67Growth\$92.P49Steroidogenesis\$91.P67Growth\$93.P68.P89Calcium\$91.P67Growth\$96.P89Calcium\$91.P67Growth\$96.P89 <t< td=""><td></td><td>\$7-\$10</td></t<>		\$7-\$10
Analogic for carly preparityS15-S18Angiogenesis as an endocrine responseS19-S22Renin-angiotensin-aldosterone axisS23-S26Endocrine autoimmunityS27-S31CLINICAL MANAGEMENT WORKSHOPSS27-S31Endocrine management of breast cancerS32-S33Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATESS39-S40Non-isotopic in-situ hybridizationS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC12-OC17GrowthOC12-OC17Endocrine pathologyOC12-OC13NeuroendocrinologyOC29-OC33Steroid genesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Bone and calciumP27-P40DiabetesP41-P56GrowthP51-P67GrowthP51-P67GrowthP68-P89Poster PRESENTATIONSP68-P89PathologyP51-P67GrowthP68-P89PathologyP51-P67GrowthP68-P89Poster PRESENTATIONSP68-P89Poster PRESENTATIONSP68-P89PathologyP51-P67GrowthP68-P89		
Angioglesis as an ender or productS19-S22Actiology of endocrine tumoursS19-S22Renin-angiotensin-aldosterone axisS23-S26Endocrine autoimmunityS27-S31CLINICAL MANAGEMENT WORKSHOPSS27-S31Endocrine management of breast cancerS32-S33Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATESS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC12-OC17ThyroidOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Bone and calciumP51-P67GrowthP68-P89		
Action by or endocrine autoinnum of a constraint of the constraint o		
Reinfrangioennia automotione and Endocrine autoimmunity\$27-\$31CLINICAL MANAGEMENT WORKSHOPS Endocrine management of breast cancer\$32-\$33Thyroid eye disease\$34-\$35Secondary osteoporosis\$36-\$38METHODS UPDATES Non-isotopic in-situ hybridization\$39-\$40Gonadotrophin bioassay versus immunoassay\$41RESEARCH COLLOQUIA Steroid action\$42, RC1-RC4Intracellular signalling\$43, RC5-RC8ORAL COMMUNICATIONS GrowthOC1-OC5ReproductionOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONS AdrenalP1-P26Bone and calciumP27-P40DiabetesP1-P26Bone and calciumP27-P40DiabetesP51-P67GrowthP68-P89Post ParticipathologyP51-P67GrowthP68-P89Post ParticipathologyP51-P67GrowthP68-P89Post ParticipathologyP51-P67GrowthP68-P89Post ParticipathologyP51-P67GrowthP68-P89SteroidogenesisP68-P89		
CLINICAL MANAGEMENT WORKSHOPS S32-S33   Endocrine management of breast cancer S32-S33   Thyroid eye disease S34-S35   Secondary osteoporosis S36-S38   METHODS UPDATES S39-S40   Gonadotrophin bioassay versus immunoassay S41   RESEARCH COLLOQUIA S42, RC1-RC4   Intracellular signalling S43, RC5-RC8   ORAL COMMUNICATIONS OC1-OC5   Growth OC12-OC17   Thyroid OC18-OC28   Neuroendocrinology OC29-OC33   Steroidogenesis OC34-OC38   POSTER PRESENTATIONS P1-P26   Bone and calcium P27-P40   Diabetes P41-P50   Endocrine pathology P51-P67   Growth P68-P89	•	
Endocrine management of breast cancerS32-S33 S34-S35Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATES Non-isotopic in-situ hybridizationS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIA Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONS GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONS AdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89POSTER PRESENTATIONSP68-P89Poster PresentationP51-P67GrowthP68-P89Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP68-P89Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P6	Endocrine autoimmunity	327-351
Endocrine management of breast cancerS32-S33 S34-S35Thyroid eye diseaseS34-S35Secondary osteoporosisS36-S38METHODS UPDATES Non-isotopic in-situ hybridizationS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIA Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONS GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONS AdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89POSTER PRESENTATIONSP68-P89Poster PresentationP51-P67GrowthP68-P89Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP68-P89Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P67Poster PresentationP51-P6	CLINICAL MANACEMENT WORKSHOPS	
Littochnic humgement of orbust cancerS34-S35Thyroid eye diseaseS36-S38METHODS UPDATESS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIAS42, RC1-RC4Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89Post PRESENTAP68-P89Post PRESENTAP68-P89Post PRESENTAP68-P89Post PRESENTAP68-P89Post PRESENTAP68-P89Post Presental StateP51-P67Bone and calciumP51-P67Post PRESENTAP68-P89Post PRESENTAP51-P67Post PRESENTAP51-P67Post PRESENTAP51-P67		\$32-\$33
Secondary osteoporosisS36-S38METHODS UPDATES Non-isotopic in-situ hybridization Gonadotrophin bioassay versus immunoassayS39-S40RESEARCH COLLOQUIA Steroid actionS42, RC1-RC4Rtracellular signallingS43, RC5-RC8ORAL COMMUNICATIONS GrowthOC1-OC5ReproductionOC1-OC5ReproductionOC12-OC17Endocrine pathology SteroidogenesisOC18-OC28POSTER PRESENTATIONS AdrenalP1-P26PostesP27-P40DiabetesP41-P50Endocrine pathology GrowthP51-P67GrowthP68-P89Poster PRESENTATIONSP68-P89		
METHODS UPDATES Non-isotopic in-situ hybridization Gonadotrophin bioassay versus immunoassayS39-S40 S39-S40 S41RESEARCH COLLOQUIA Steroid actionS42, RC1-RC4 S43, RC5-RC8ORAL COMMUNICATIONS GrowthOC1-OC5 OC6-OC11 Endocrine pathologyORAL COMMUNICATIONS GrowthOC1-OC5 OC6-OC11 OC12-OC17 ThyroidPOSTER PRESENTATIONS AdrenalP1-P26 P27-P40 DiabetesPOSTER PRESENTATIONS GrowthP27-P40 P21-P50 P51-P67 Growth	• •	
Non-isotopic in-situ hybridizationS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIASteroid actionSteroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC29-OC33NeuroendocrinologyOC34-OC28POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-R89GrowthP68-R89GrowthP09 D08	Secondary osteoporosis	000 000
Non-isotopic in-situ hybridizationS39-S40Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIASteroid actionSteroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC29-OC33NeuroendocrinologyOC34-OC28POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-R89GrowthP68-R89GrowthP09 D08	METHODS LIPDATES	
Gonadotrophin bioassay versus immunoassayS41RESEARCH COLLOQUIASteroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89Order of the pathologyP51-P67GrowthP68-P89		S39-S40
RESEARCH COLLOQUIAS42, RC1-RC4Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89GrowthP68-P89	•	S41
Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89GrowthP08-P89	Gonadotrophini bioassay versus minianoassay	
Steroid actionS42, RC1-RC4Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89GrowthP08-P89	RESEARCH COLLOOUIA	
Intracellular signallingS43, RC5-RC8ORAL COMMUNICATIONSOC1-OC5GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSAdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89GrowthP0800		S42, RC1-RC4
ORAL COMMUNICATIONSOC1-OC5GrowthOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSAdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89GrowthP08-P09		S43, RC5-RC8
GrowthOC1-OC5ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSAdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89	Inducedura Subjection D	
CirowinOC6-OC11ReproductionOC6-OC11Endocrine pathologyOC12-OC17ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSAdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89	ORAL COMMUNICATIONS	
ReproductionOC12-OC17Endocrine pathologyOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSAdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-P89DO02P08-P89D002P08-P89D003P08-P89	Growth	
Endocrine pathologyOC18-OC28ThyroidOC29-OC33NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-P89	Reproduction	
ThyroidOC18-OC28NeuroendocrinologyOC29-OC33SteroidogenesisOC34-OC38POSTER PRESENTATIONSAdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-P89	Endocrine pathology	
Neurocinicol gyOC34-OC38SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-P89		OC18-OC28
SteroidogenesisOC34-OC38POSTER PRESENTATIONSP1-P26AdrenalP27-P40Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP08-P89	Neuroendocrinology	
AdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89		OC34-OC38
AdrenalP1-P26Bone and calciumP27-P40DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89		
AdrenalP27-P40Bone and calciumP41-P50DiabetesP41-P50Endocrine pathologyP51-P67GrowthP68-P89Doo P08	POSTER PRESENTATIONS	D4 D2(
DiabetesP41-P50DiabetesP51-P67Endocrine pathologyP68-P89GrowthP00 P08	Adrenal	
Endocrine pathology P51-P67 Growth P68-P89	Bone and calcium	
Growth P68-P89	Diabetes	
	Endocrine pathology	
Methodology P90-P98	Growth	
	Methodology	P90-P98

**DOCKET A L A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Neuroendocrinology Pituitary Regulatory peptides Reproduction Thyroid

P99-P121 P122-P152 P153-P165 P166-P207 P208-P237

# **INDEX OF FIRST AUTHORS**

**DOCKET A L A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

٠

.

#### P183 THE EFFECTS OF ICI 182,780, A PURE ANTI-OESTROGEN, ON REPRODUCTIVE ENDOCRINOLOGY IN NORMAL PRE-MENOPAUSAL WOMEN

E.J. Thomas<sup>1</sup>, N.M. Thomas<sup>1</sup>, P.L. Walton<sup>2</sup> and M. Dowsett<sup>3</sup>

<sup>1</sup>Obstetrics and Gynaecology, Southampton, <sup>2</sup>ICI Pharmaceuticals, Alderley Edge and <sup>3</sup>Biochemistry, Royal Marsden Hospital

ICI 182,780 has been found in vitro and in animal models to exert a pure anti-oestrogenic action with no agonist activity. 19 pre-menopausal women were prescribed 182,780, 12 mg intramuscularly, daily for 7 seven days prior to hysterectomy starting between day 5 to day 9 of the menstrual cycle, for benign gynaecological disease. 11 controls were also recruited. No significant adverse events were reported in either group. 3 women in the treatment group were withdrawn because of endocrine abnormalities or because they were in the luteal phase at the beginning of treatment. 12 of the 16 remaining treated women showed a consistent response to ICI 182,780 characterised by no increase in the plasma concentration of LH and FSH, no LH surge, continuing follicular growth ultrasonically, increasing plasma oestradiol concentrations, no increase in endometrial thickness and no ultrasonic evidence of ovarian hyperstimulation. The remaining 4 women showed an increase in endometrial thickness in parallel with an increase in plasma oestradiol concentration. Overall plasma oestradiol concentrations were significantly higher in the treated group compared with control group over the sampling interval. Pharmacodynamic data are being analyzed. Overall the results suggest that in a majority of pre-menopausal women ICI 182,780, 12 mg daily for 7 days does not stimulate gonadotrophin secretion and will suppress endometrial growth in spite of continuing oestradiol stimulation. The absence of adverse events or of evidence of ovarian hyperstimulation suggests that this compound may be able to be used for the treatment of oestrogen dependent diseases in pre-menopausal women.

P184 COMPARISONS OF THE BIOACTIVITY OF FEMALE RAT PITUITARY AND PLASMA LH

A.J. Leigh, T. Shakil<sup>\*</sup>, S.A. Fickling+ and C.A. Wilson. Departments Obstetrics & Gynaecology, Physiology<sup>\*</sup> and Cellular & Molecular Science+, St. George's Hospital Medical School, London SW17 ORE.

Pituitary and plasma LH possess different physico-chemical characteristics (1). We have now compared their bioactives "in vitro", investigating their ability to stimulate the production of testosterone, progesterone and tissue plasminogen activator (tPA).

Pituitaries (n=9) and plasma (n=7) were collected on proestrus, the former were homogenised in buffer and the supernatant diluted 1:500. All samples were assayed by radioimmunoassay (RIA;NIH-RP3 standard) and the mouse Leydig cell bioassay. Samples were incubated for 48 hours with cultured granulosa cells isolated from rat ovarian follicles ( $\geq 400 \ \mu$ M diameter) and then the culture medium was assayed for progesterone by RIA. Samples were also incubated for 48 hours with SV40 transected human umbilical vein endothelial cells (SGHEC7) and the incubate assayed for total tPA by Elisa.

Results standardised to the concentration of steroid or tPA produced per ng of immunogenic LH showed that the ratio of plasma to pituitary activity was 4.1:1 for testosterone production; 3.8:1 for progesterone production, while for tPA, plasma LH produced  $107\pm16.5$  ng/ml/ng LH (n=7) but pituitary LH applied to the cells at  $4.9\pm0.2$  ng (n=9) was inactive.

These findings indicate that on release of LH from the pituitary gland into the circulation, there is a 4-fold increase in steroidogenic activity of LH, and also an increase in it's ability to produce tPA 1. Leigh, A.J., Chapman, A.J. & Wilson, C.A. J. Reprod. Fertil. Abstract Series 3. No 115 (1989).

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.